<DOC>
	<DOCNO>NCT00772070</DOCNO>
	<brief_summary>This study design simulate meningococcal challenge vaccination fractional combine dose unconjugated meningococcal polysaccharide A , C , Y , W-135 , Menomune® child vaccinate one dose TetraMenD least 18 month earlier . Primary Objective : To evaluate compare antibody response reduce dose Menomune® participant previously receive tetravalent meningococcal diphtheria toxoid conjugate vaccine responses participant receive reduce dose Menomune® previously receive meningococcal vaccine .</brief_summary>
	<brief_title>Study Reduced Dose Menomune® Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine</brief_title>
	<detailed_description>This two stage , control , open-label trial . Stage I trial simulate meningococcal challenge Stage II trial evaluate meningococcal vaccine naïve participant Stage I , also receive reduce dose Menomune® vaccine Stage I administer full dose Menactra® vaccine 6 month later .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Stage I Participant healthy , determined medical history physical examination . Participant least 3 year age yet 6 year age enrolment . For TetraMenD group : receive one dose TetraMenD participant trial 60302 less 18 month prior enrolment For Control group : previous history meningococcal vaccination Parent/Guardian sign Institutional Review Board ( IRB ) approve informed consent form . Stage II Participant healthy , determined medical history physical examination . Participant least 3 year age yet 6 year age time enrollment Stage 1 . Enrolled Control group receive one dose reduce dose Menomune Stage 1 . Parent/Guardian sign Institutional Review Board ( IRB ) approve informed consent form . Exclusion Criteria : Serious chronic disease ( i.e. , cardiac , renal , neurologic , metabolic , rheumatologic , psychiatric etc . ) Known suspect impairment immunologic function Acute medical illness without fever within last 72 hour axillary temperature ( ≥ 99.5ºF [ ≥ 37.5ºC ] ) time inclusion For Stage I , history document invasive meningococcal disease previous meningococcal vaccination exception participant recruit Trial 60302 . For Stage II , history document invasive meningococcal disease participant receive Reduceddose Menomune® six month prior . Administration immune globulin , blood product within last three month , injected oral corticosteroid immunomodulatory therapy within six week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day may include trial long receive one course within last two week prior enrollment . Antibiotic therapy within 72 hour prior vaccination antibiotic therapy within 72 hour prior blood sample drawn Received vaccine 28day period prior study vaccination , schedule receive vaccination 28day period study vaccination Stage 1 trial . Suspected known hypersensitivity vaccine component Unavailable entire study period unable attend schedule visit comply study procedure Enrolled another clinical trial Any condition , , opinion investigator , would pose health risk participant interfere evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Menactra®</keyword>
	<keyword>Menomune®</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcemia</keyword>
	<keyword>Neisseria meningitidis</keyword>
</DOC>